Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Blocco TAP guidato visivamente nella riparazione laparoscopica dell'ernia TAPP (VIS-TAP-TAPP)

14 novembre 2026 aggiornato da: Łukasz Dyśko, University of Warmia and Mazury in Olsztyn

Efficacia del Blocco del Piano Trasverso dell'Addome (TAP) Guidato Visivamente nel Recupero Dopo la Riparazione Laparoscopica dell'Ernia Inguinale (TAPP - Transaddominale Preperitoneale)

This prospective, randomized, placebo-controlled clinical study evaluates the effectiveness of a bilateral transversus abdominis plane (TAP) block performed under direct laparoscopic guidance in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique.

Adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland, are randomly assigned to two groups. In the experimental group, a bilateral TAP block is performed after establishing pneumoperitoneum, using 20 mL of 0.25% bupivacaine on each side (40 mL total; 100 mg total). In the control group, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same technique and anatomical sites.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Postoperative assessments include pain intensity measured using the Visual Analogue Scale (VAS), analgesic consumption, the need for rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using the Post-Anesthetic Discharge Scoring System (PADSS), and adverse events.

The study compares postoperative pain and recovery outcomes between patients receiving laparoscopically guided TAP block with bupivacaine and those receiving placebo saline injections.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Postoperative pain remains an important factor limiting early mobilization and recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Multimodal analgesia combines systemic analgesics with additional approaches, including regional anesthesia. A transversus abdominis plane (TAP) block targets nerves supplying the abdominal wall and can be performed under direct laparoscopic guidance during surgery.

This single-center, prospective, randomized, placebo-controlled study evaluates the effect of a laparoscopically guided bilateral TAP block on postoperative pain and recovery after elective TAPP inguinal hernia repair at the University Clinical Hospital in Olsztyn, Poland.

The planned sample size is 116 adult participants, allocated in a 1:1 ratio to two groups of 58 participants each:

Experimental group: After pneumoperitoneum is established and the laparoscope is introduced, a bilateral TAP block is performed under direct laparoscopic guidance before mesh placement. Bupivacaine 0.25% is injected at a volume of 20 mL per side, corresponding to 50 mg per side and 100 mg in total. The injection site is approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic elevation of the transversus abdominis muscle layer, known as the "Doyle's bulge sign."

Placebo control group: Participants undergo the same TAPP repair and receive bilateral injections of 0.9% sodium chloride, 20 mL per side (40 mL total), using the same injection technique and anatomical sites as in the experimental group.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Analgesic administration and the timing of rescue medication are recorded.

Postoperative pain intensity is assessed using the Visual Analogue Scale (VAS; 0-10) at 0, 2, and 6 hours after the end of surgery. Site-specific assessments include the umbilical port site, the working trocar site on the operated side, the working trocar site on the opposite side, the operated groin, and the ipsilateral testicle, where applicable. Additional assessments include time to first mobilization, analgesic consumption, rescue analgesic use, and readiness for discharge using the Post-Anesthetic Discharge Scoring System (PADSS) at 6 hours. Adverse events, including hematoma, swelling, subcutaneous emphysema, and transient lower limb weakness, are recorded during the 6-hour postoperative observation period.

Exclusion criteria include chronic analgesic use, chronic pain syndromes, psychiatric disorders, alcohol or opioid dependence, recurrent hernias, and emergency surgery. All participants provide written informed consent before enrollment.

The primary outcome is postoperative pain intensity at rest measured using the VAS at 2 hours after the end of surgery. Secondary outcomes include pain intensity at 0 and 6 hours, site-specific pain intensity, analgesic consumption during the first 6 hours, the proportion of participants requiring rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using PADSS at 6 hours, and adverse events.

Statistical analyses compare postoperative pain, analgesic requirements, and recovery outcomes between the bupivacaine and placebo groups. The study hypothesis is that a laparoscopically guided bilateral TAP block with bupivacaine reduces postoperative pain and improves early recovery compared with placebo saline injections.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

116

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Warmisko-mazurskie
      • Olsztyn, Warmisko-mazurskie, Polonia, 10-041
        • University Clinical Hospital in Olsztyn, Department of General and Oncological Surgery

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18-80 years
  • Elective laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique
  • ASA physical status I-III
  • Ability to provide written informed consent
  • No contraindications to regional anesthesia or local anesthetic administration

Exclusion Criteria:

  • Recurrent or strangulated inguinal hernia
  • Emergency surgery
  • Chronic pain syndromes or preoperative opioid use
  • Known allergy or hypersensitivity to local anesthetics (bupivacaine or similar)
  • Severe hepatic or renal impairment
  • Psychiatric disorders or inability to provide informed consent
  • Conversion to open surgery during the procedure
  • Technical difficulties preventing TAP block administration

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TAP Block Group (Laparoscopic TAP Block with Bupivacaine)

After pneumoperitoneum is established and the laparoscope is introduced, a bilateral Transversus Abdominis Plane (TAP) block is performed under direct laparoscopic vision. Using a needle and syringe, 20 ml of 0.25% bupivacaine is injected on each side, approximately 2 cm below the costal margin in the anterior axillary line. The correct placement of the local anesthetic is confirmed by the visible "Doyle's bulge sign." Patients receive standard general anesthesia and postoperative pain management identical to the control group.

A bilateral transversus abdominis plane (TAP) block is performed under direct laparoscopic guidance after pneumoperitoneum is established and before mesh placement during TAPP inguinal hernia repair. Using a needle and syringe, 20 mL of 0.25% bupivacaine is injected on each side (40 mL total; 100 mg total), approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic "Doyle's bulge sign." This technique allows direct laparoscopic visualization of the injection site.

Altri nomi:
  • TAPP con TAP Block
Comparatore placebo: Control Group (Placebo Saline Injection)

Participants undergo standard laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Instead of bupivacaine, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same visually guided injection technique and anatomical sites as in the experimental group. All patients receive the same standardized general anesthesia protocol and postoperative analgesic regimen as those in the experimental group.

Bilateral injection of 0.9% sodium chloride, 20 mL per side (40 mL total), into the transversus abdominis plane under laparoscopic visual guidance. The placebo is administered at the same anatomical sites and using the same technique as bupivacaine in the experimental group. An operating room nurse prepares a visually identical syringe without disclosing its contents to the operating surgeon.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative pain intensity at rest (VAS score) at 2 hours after TAPP hernia repair
Lasso di tempo: 2 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), at 2 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation. Scores are compared between the bupivacaine TAP block group and the placebo saline injection group.

2 hours after the end of surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative pain intensity at rest (VAS score) at 0 and 6 hours after surgery
Lasso di tempo: 0 and 6 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), immediately after surgery (0 hours) and at 6 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation.

0 and 6 hours after the end of surgery
Time to first mobilization
Lasso di tempo: Within 6 hours after the end of surgery

The time (in hours) from the end of surgery to the patient's first ambulation will be recorded.

Within 6 hours after the end of surgery
Postoperative recovery score (PADSS)
Lasso di tempo: 6 hours after surgery

Recovery will be assessed using the Post Anesthesia Discharge Scoring System (PADSS), 0-10; higher scores indicate greater readiness for discharge. A score ≥9 will indicate readiness for discharge.

6 hours after surgery
Incidence of postoperative complications
Lasso di tempo: Within 6 hours after the end of surgery

Early postoperative complications such as hematoma, swelling, subcutaneous emphysema, or transient lower limb weakness will be recorded.

Within 6 hours after the end of surgery
Participants requiring rescue opioid analgesia
Lasso di tempo: First 6 hours after the end of surgery

Proportion of participants receiving rescue oxycodone during the first 6 postoperative hours.

First 6 hours after the end of surgery
Total oxycodone consumption
Lasso di tempo: First 6 hours after the end of surgery

Total dose of oxycodone administered to each participant, expressed in milligrams.

First 6 hours after the end of surgery
Total metamizole consumption
Lasso di tempo: First 6 hours after the end of surgery

Total dose of metamizole administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Total paracetamol consumption
Lasso di tempo: First 6 hours after the end of surgery

Total dose of paracetamol administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Time to first analgesic request
Lasso di tempo: First 6 hours after the end of surgery

Time in hours from the end of surgery to the participant's first request for analgesic medication.

First 6 hours after the end of surgery
Site-specific postoperative pain intensity
Lasso di tempo: 0, 2, and 6 hours after the end of surgery

Pain intensity is assessed using the VAS (0-10; higher scores indicate worse pain) separately at the umbilical port site, ipsilateral and contralateral working trocar sites, operated groin, and ipsilateral testicle, where applicable.

0, 2, and 6 hours after the end of surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Marek Kowalczyk, PhD, MD, Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 dicembre 2025

Completamento primario (Effettivo)

31 ottobre 2026

Completamento dello studio (Effettivo)

31 ottobre 2026

Date di iscrizione allo studio

Primo inviato

23 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

23 novembre 2025

Primo Inserito (Effettivo)

4 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • UWM-TAP-TAPP-2025
  • 19/2025/IX (Altro identificatore: Ethics Committee Approval Number - Warmian-Masurian Chamber of Physicians in Olsztyn)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) will not be shared because this is a single-center, investigator-initiated academic study involving a limited number of participants. The collected data include sensitive personal and clinical information that cannot be fully anonymized without compromising data integrity. Only aggregated, de-identified results will be published in peer-reviewed journals and conference presentations.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .